Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative
Online education and training
Order products online
Reimbursement resources
Return a product
Customer support

Call customer care

1 (888) 272-1001

Illustration of the Eluvia Drug-eluting Stent System.

Eluvia Outlasts Zilver PTX, Outperforms Expectations.

Eluvia DES Elutes Paclitaxel When It’s Most Critical. Zilver PTX’s Falls Short.

Drug release over time with Eluvia DES, DCB, and Zilver PTX.

Eluvia DES is the only SFA drug-eluting stent with a polymer coating, enabling a sustained drug release to match the SFA restenotic cascade.2

The polymer:

  • Maintains a steady release of paclitaxel during the height of restenosis
  • Protects the drug from dissolving in the blood
  • Ensures highly controlled drug delivery to the target lesion.

Eluvia DES releases paclitaxel for ~365 days. In comparison - Zilver PTX, a drug-coated stent without a polymer, releases all paclitaxel within 72 hours and paclitaxel is detectable in tissue through only 56 days.3

Most restenosis and TLR events occur within the first 12–24 months. Choose the stent that is engineered for efficient and sustained drug elution through the height of restenosis.

Download the Datasheet

Eluvia delivers unrivaled clinical outcomes at 1 and 2 years, the time period that matters most.

We are so confident in Eluvia's technology, we put Eluvia to the test in the IMPERIAL RCT, the world's first head-to-head DES SFA trial. Not surprisingly, Eluvia prevailed.​

At 1 year, Eluvia demonstrated statistical superiority over Zilver PTX​4,5.
At 2 years, Eluvia delivered statistically lower revascularization rates than Zilver PTX6.

Eluvia DES demonstrated superiority over Zilver PTX at 1 year4

IMPERIAL RCT

Chart with Primary Patency Results* 92.1% Eluvia DES 81.8% Zilver PTX

Eluvia DES delivered statistically lower revascularization rates vs. Zilver PTX at 2 years.6

IMPERIAL RCT

2-YEAR CLINICALLY-DRIVEN TLR

Eluvia DES has a thirty-five percent reduction in repeat procedures versus Zilver PTX.

Need More Proof?

In an SFA stent meta-analysis that assessed more than 142 publications with 52,000 patients, Eluvia demonstrated higher primary patency and lower TLR rates than BMS, Viabahn and Zilver PTX at 1 and 2 years, no matter the length of the lesion.7

Primary Patency

Eluvia primary patency infographic.

Target Lesion Revascularization

Eluvia target lesion revascularization infographic.

No matter the patient, no matter the lesion - Eluvia DES outcomes are consistent.

Chart showcasing 1 Year primary patency and average lesion length; Eluvia DES vs. Zilver PTX.
Eluvia DES is the most implanted SFA Stent.

When a stent is needed, don't settle for less, choose Eluvia DES.

Eluvia indications, safety, and warnings

Footnotes:

*Data on file at Boston Scientific. DRG US hospital market data, June 2025.
1. Iida, O. et al. Catheterization and Cardiovascular Interventions. 2011; 78:611-617.
2. Müller-Hülsbeck S. Expert Opin Drug Deliv. 2016;13(11):1639–1644.
3. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610);
4. Superiority determined in a post hoc analysis that was specificed prior to unbinding. 12-Month Primary Patency rate of 86.8% in the Eluvia arm vs. 77.5% in the Zilver PTX arm (p-value=0.0144). Gray WA, Lancet, 2018 Sep 24. pii:S01406736(18)32262-1.
5. Gray WA, LINC 2020
6. Müller-Hülsbeck S, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol. 2021;44(3):368-375. doi:10.1007/s00270-020-02693-1
7. Holden, A. Performance of Stenting in Femoropopliteal Disease: Systematic Literature Review and Meta-analysis of Proportions. Presented at Charing Cross 2025.